Tags

Type your tag names separated by a space and hit enter

Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway.
Chin J Integr Med. 2020 Jul 09 [Online ahead of print]CJ

Abstract

OBJECTIVE

To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-ai injection (KAI,) in gastric cancer cells.

METHODS

Gastric cancer cell lines MGC803 and BGC823 were treated by 0, 0.3%, 1%, 3% and 10% KAI for 24, 48 and 72 h, respectively. The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The apoptosis and cell cycle were evaluated by flow cytometry. Interleukin (IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immune sorbent assay (ELISA), respectively. The protein expression levels of cyclin A, cyclin E, cyclin B1, cyclin D1, p21, retinoblastoma (RB), protein kinase B (AKT), extracellular regulated protein kinases (ERK), signal transducer and activator of transcription (STAT) 1 and STAT3 were detected by Western blot.

RESULTS

KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose- and time-dependent manner. After treated with KAI for 48 h, the proportion of G1 phase was increased, expression level of cyclin D1 and phosphorylation-RB were down-regulated, whereas the expression of p21 was up-regulated (all P<0.01). Furthermore, 48-h treatment with KAI decreased the phosphorylation level of STAT3, inhibited the mRNA and protein expressions of IL-6 (all P<0.01). IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3% and 10% KAI, and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level (all P<0.01).

CONCLUSION

KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G1 phase arrest in gastric cancer cells.

Authors+Show Affiliations

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China.Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. xfche@cmu.edu.cn. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China. xfche@cmu.edu.cn. Liaoning Province Clinical Research Center for Cancer, Shenyang, 110001, China. xfche@cmu.edu.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32648126

Citation

Zheng, Chun-Lei, et al. "Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation Through IL-6/STAT3 Pathway." Chinese Journal of Integrative Medicine, 2020.
Zheng CL, Hou KZ, Wang AQ, et al. Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway. Chin J Integr Med. 2020.
Zheng, C. L., Hou, K. Z., Wang, A. Q., Fang, W. X., Yu, S. T., Liang, J. E., Qi, H. Y., Qu, X. J., Liu, Y. P., & Che, X. F. (2020). Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-020-3265-6
Zheng CL, et al. Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation Through IL-6/STAT3 Pathway. Chin J Integr Med. 2020 Jul 9; PubMed PMID: 32648126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kang-ai Injection () Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway. AU - Zheng,Chun-Lei, AU - Hou,Ke-Zuo, AU - Wang,An-Qi, AU - Fang,Wan-Xia, AU - Yu,Shi-Tong, AU - Liang,Jin-E, AU - Qi,Hai-Yan, AU - Qu,Xiu-Juan, AU - Liu,Yun-Peng, AU - Che,Xiao-Fang, Y1 - 2020/07/09/ PY - 2019/12/26/accepted PY - 2020/7/11/entrez KW - Chinese herbal medicine KW - G1 arrest KW - Kang-ai Injection KW - gastric cancer KW - interleukin-6 KW - signal transducer and activator of transcription 3 JF - Chinese journal of integrative medicine JO - Chin J Integr Med N2 - OBJECTIVE: To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-ai injection (KAI,) in gastric cancer cells. METHODS: Gastric cancer cell lines MGC803 and BGC823 were treated by 0, 0.3%, 1%, 3% and 10% KAI for 24, 48 and 72 h, respectively. The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The apoptosis and cell cycle were evaluated by flow cytometry. Interleukin (IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immune sorbent assay (ELISA), respectively. The protein expression levels of cyclin A, cyclin E, cyclin B1, cyclin D1, p21, retinoblastoma (RB), protein kinase B (AKT), extracellular regulated protein kinases (ERK), signal transducer and activator of transcription (STAT) 1 and STAT3 were detected by Western blot. RESULTS: KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose- and time-dependent manner. After treated with KAI for 48 h, the proportion of G1 phase was increased, expression level of cyclin D1 and phosphorylation-RB were down-regulated, whereas the expression of p21 was up-regulated (all P<0.01). Furthermore, 48-h treatment with KAI decreased the phosphorylation level of STAT3, inhibited the mRNA and protein expressions of IL-6 (all P<0.01). IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3% and 10% KAI, and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level (all P<0.01). CONCLUSION: KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G1 phase arrest in gastric cancer cells. SN - 1672-0415 UR - https://www.unboundmedicine.com/medline/citation/32648126/Kang-ai_Injection_()_Inhibits_Gastric_Cancer_Cells_Proliferation_through_IL-6/STAT3_Pathway L2 - https://dx.doi.org/10.1007/s11655-020-3265-6 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.